- Report
- August 2025
- 189 Pages
Global
From €3496EUR$3,939USD£3,009GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2663EUR$3,000USD£2,292GBP
- Drug Pipelines
- April 2025
- 50 Pages
Global
From €1331EUR$1,500USD£1,146GBP
- Report
- October 2024
- 331 Pages
Global
From €7057EUR$7,950USD£6,073GBP
- Report
- June 2025
- 200 Pages
Global
From €2476EUR$2,789USD£2,131GBP
- Report
- May 2024
- 130 Pages
Global
From €5769EUR$6,499USD£4,965GBP
- Report
- May 2024
- 133 Pages
Global
From €5769EUR$6,499USD£4,965GBP
- Report
- May 2024
- 128 Pages
Global
From €5769EUR$6,499USD£4,965GBP
- Report
- August 2023
- 74 Pages
Canada
From €3107EUR$3,500USD£2,674GBP
- Report
- February 2022
- 220 Pages
Global
From €8432EUR$9,500USD£7,258GBP
Vericiguat is a novel drug class of cardiovascular drugs used to treat heart failure. It is a soluble guanylate cyclase (sGC) stimulator, which works by increasing the production of cyclic guanosine monophosphate (cGMP) in the body. This helps to relax the blood vessels, allowing more blood to flow to the heart and improving its function. Vericiguat is approved for use in adults with chronic heart failure with reduced ejection fraction (HFrEF). It is also being studied for use in other cardiovascular conditions, such as hypertension and coronary artery disease.
Vericiguat is a relatively new drug class, and is currently only available from a few companies. These include Bayer, Novartis, and Merck. Other companies are also researching and developing vericiguat-based drugs, such as Pfizer, GlaxoSmithKline, and AstraZeneca. Show Less Read more
